Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabinol topical - InMed Pharmaceuticals

Next Previous
Drug Profile

Cannabinol topical - InMed Pharmaceuticals

Alternative Names: INM 755; INM-750

Latest Information Update: 30 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InMed Pharmaceuticals
  • Class Antiallergics; Antiglaucomas; Cannabinoids; Neuroprotectants; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Apoptosis inhibitors; Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Epidermolysis bullosa

Highest Development Phases

  • Phase II Epidermolysis bullosa

Most Recent Events

  • 22 Jan 2025 InMed Pharmaceuticals has patent granted for Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders Method of Use in USA, Australia, Japan, Israel
  • 29 Sep 2023 Cannabinol topical - InMed Pharmaceuticals is available for licensing as of 29 Sep 2023. http://sntpseditorial/adis2000www/script/citation/citationmain.asp?Adnm=
  • 26 Jun 2023 Interim efficacy data from a phase I 755-101-HV Epidermolysis Bullosa released by InMed Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top